Eli Lilly and Company (LLY) Stock

Eli Lilly and Company (LLY) is a Healthcare stock trading at $1099.30 (as of 2026-06-18), with a market capitalization of $1.04T and a trailing P/E of 39.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Eli Lilly and Company develops, manufactures, and markets human pharmaceutical products worldwide. Its portfolio includes diabetes medicines and therapies across oncology, immunology, and other therapeutic areas, serving patients and healthcare providers globally.

Valuation — source: SEC EDGAR (first-party)
Price$1099.30
Market Cap$1.04T
P/E Ratio39.3
EV / EBITDA32.5
Price / Book33.36
Price / Sales14.40
Dividend Yield0.5%
DCF Value (model)$412.35
DCF Upside vs Price-62.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$65.18B
Net Margin31.7%
Return on Equity81.0%
Debt / Equity1.39
Current Ratio1.50
Revenue Growth (YoY)55.5%
EPS Growth (YoY)169.4%
Financial Health — source: SEC EDGAR
Altman Z-Score9.10 (safe)
Piotroski F-Score8/9 (strong)
Valuation vs Sector & Industry
Stock P/E39.3
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector87.3%
vs Industry127.4%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Insider Sells (12mo)47
Top Institutional HolderVANGUARD GROUP INC ($88.09B)
Institutional Holders Tracked10
Congressional Trades (recent)10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEODavid A. Ricks
Employees47,000
CountryUS
IPO Date1972-06-01

Related Companies (Business model: Big Pharma / Branded Drugs; 8 closest by market cap; US-domiciled)

  • Johnson & Johnson (JNJ)
  • AbbVie Inc. (ABBV)
  • Merck & Co., Inc. (MRK)
  • Abbott Laboratories (ABT)
  • Amgen Inc. (AMGN)
  • Gilead Sciences, Inc. (GILD)
  • Pfizer Inc. (PFE)
  • Bristol-Myers Squibb Company (BMY)
LLY earnings history · LLY institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.